Overview
The aim of this study is to determine the expression of STIM1 in the plasma membrane of lymphocytes from patients suffering from different autoimmune diseases in order to identify new pathologies of interest presenting an over-expression of STIM1PM.
This would allow to initiate, following this study, research and development programs on the use of anti-STIM1 antibodies in these identified autoimmune diseases of interest.
Eligibility
Inclusion Criteria:
- Diagnosis of one of the autoimmune diseases
Exclusion Criteria:
- Treatment with rituximab in the previous 12 months